Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: Its safety in a combination with oral calcium carbonate

Cohen, 1991, Lipid abnormalities in renal disease, Kidney Int, 39, 169, 10.1038/ki.1991.22 Senti, 1992, Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure, Kidney Int, 41, 1394, 10.1038/ki.1992.204 Avram, 1989, Cholesterol and lipid disturbances in renal disease: The natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis, Am J Med, 87, 55N Pan, 1995, A study on the relative factors for secondary parathyroidosis and renal osteodystrophy in long-term hemodialysis patients, Chung Hua Nei Ko Tsa Chih, 34, 161 Turk, 1992, Effect of 1,25 (OH) 2D3 treatment on glucose intolerance in uraemia, Nephrol Dial Transplant, 7, 1207, 10.1093/ndt/7.12.1207 Sardar, 1996, Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague-Dawley rats, Int J Vitam Nutr Res, 66, 39 Lind, 1988, A pilot study of metabolic effects of intravenously given alpha-calcidol in patients with chronic renal failure, Scand J Urol Nephrol, 22, 219, 10.1080/00365599.1988.11690415 Yeksan, 1992, Effects of 1.25 (OH) 2D3 treatment on lipid levels in uremic hemodialysis patients, Int J Artif Organs, 15, 704, 10.1177/039139889201501204 Khajehdehi, 2000, Effect of vitamins on the lipid profile of patients on regular hemodialysis, Scand J Urol Nephrol, 34, 62, 10.1080/003655900750016913 Mak, 1998, 1,25 dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia, Kidney Int, 53, 1353, 10.1046/j.1523-1755.1998.00865.x Tsukamoto, 1991, The ‘oral 1,25-dihydroxyvitamin D3 pulse therapy’ in hemodialysis patients with severe secondary hyypeparathyroidism, Nephron, 57, 23, 10.1159/000186210 Sherrard, 1993, The spectrum of bone disease in end-stage renal failure—an evolving disorder, Kidney Int, 43, 436, 10.1038/ki.1993.64 Monier-Faugere, 1996, Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients, Nephrol Dial Transplant, 11, 111, 10.1093/ndt/11.supp3.111 Block, 1998, Association of serum phosphorous and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study, Am J Kidney Dis, 31, 607, 10.1053/ajkd.1998.v31.pm9531176 Block, 2000, Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendation for a change in management, Am J Kidney Dis., 35, 1226, 10.1016/S0272-6386(00)70064-3 Slatopolsky, 2000, A novel mechanism for skeletal resistance in uremia, Kidney Int, 58, 753, 10.1016/S0085-2538(15)47156-X Cannata-Andia, 1998, Hypokinetic azotemic osteodystrophy, Kidney Int, 54, 1000, 10.1046/j.1523-1755.1998.00080.x Goodman, 2000, Coronary-artery alcification in young adults with end-stage renal disease who are undergoing dialysis, N Engl J Med, 342, 1478, 10.1056/NEJM200005183422003 Maggie, 1994, Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated athersclerosis?, Kidney Int, 45, 876, 10.1038/ki.1994.115 Westhuvzen, 1995, Evidence for oxidative stress during in vitro dialysis, Nephron, 70, 49, 10.1159/000188543 Maclin, 1995, Critical assessment of the epidemiological data concerning the impact of the antioxidant nutrients on cancer and cardiovascular disease, Crit Rev Food Sci Nutr, 35, 41, 10.1080/10408399509527684 Ljunghall, 1983, Dibetes melitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy, Eur J Clin Invest, 13, 373, 10.1111/j.1365-2362.1983.tb00116.x Amend, 1985, The influence of serum calcium and parathyroid hormone upon glucose metabolism in uremia, J Lab Clin Med, 86, 435 Nishizawa, 1997, Atherosclerosis in uremia: Possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation, Kidney Int, 52, S90 Vaziri, 1999, Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure, Nephrol Dial Transplant, 14, 1462, 10.1093/ndt/14.6.1462